Core Viewpoint - The article presents the "Top 10 CO2 Incubator Products of 2025" based on user interest and browsing statistics, highlighting the growing attention towards domestic brands in the CO2 incubator market [2][4]. Summary by Sections Top 10 CO2 Incubator Products - The ranking includes products from both domestic and international brands, with the top three being: 1. Suzhou Beiyin's BIO-150RHP 2. WIGGENS' WCI-180 3. Haier Biomedical's HCP-168 [2][4]. Domestic vs. International Brands - Six out of the ten products are from domestic brands, indicating a significant user preference for local options. Suzhou Beiyin's product leads the list, while Haier Biomedical has two models in the top rankings [4]. - International brands such as WIGGENS, Thermo Scientific, and Esco maintain a strong presence, particularly in the high-end market, showcasing their technological advantages and brand reputation [4]. User Interest and Market Trends - The increased attention towards domestic CO2 incubators is attributed to policy incentives like "large-scale equipment updates" and changes in the international trade environment, which accelerate the domestic replacement process [4]. - The improvement in domestic brands' technological capabilities, manufacturing quality, and product reliability is also noted as a factor in gaining user trust and market recognition [4]. Product Features Overview - The article provides a brief introduction to each of the top products, highlighting key features such as: - Suzhou Beiyin's BIO-150RHP includes GMP-compliant data management and advanced temperature control systems [5][7]. - WIGGENS' WCI-180 features a direct heating system and dual-beam CO2 sensors for accurate monitoring [9][11]. - Haier Biomedical's HCP-168 utilizes fuzzy PID control for precise temperature management and includes a high-efficiency microbial filter [12][14]. Conclusion - The "Top 10 CO2 Incubator Products of 2025" reflects the evolving landscape of the CO2 incubator market, with a notable shift towards domestic brands gaining traction among users due to improved technology and favorable market conditions [4][36].

Core Viewpoint - Haier Biomedical focuses on providing AI-driven automated solutions for life sciences users, including pharmaceutical companies, research institutions, hospitals, and public health organizations, with products applied in over 150 countries and regions [1] Group 1 - The company targets pharmaceutical and life sciences sectors, as well as healthcare users such as hospitals and disease control centers [1] - Haier Biomedical integrates "AI + automation" into its products and solutions, enhancing their capabilities [1] - The solutions cover various fields, including low-temperature storage, laboratory applications, hospital medication, and blood technology [1]

Group 1 - The core point of the article is that Haier Biomedical has reported the total number of its shareholders as of January 10, 2026, which stands at 13,313 households [2]

证券代码：688139 证券简称：海尔生物 公告编号：2026-004 青岛海尔生物医疗股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/14 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 日~2026 年 月 13 | 1 | 月 | 14 | 1 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | 回购价格上限 | 49.5367元/股 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 实际回购股数 | 3,087,899股 | | | | | | 实际回购股数占总股本比例 | 0.9757% | | | | | | 实际回购金 ...

Group 1 - The company Haier Biomedical (688139.SH) completed a share buyback on January 13, 2026, repurchasing a total of 3,087,899 shares, which represents 0.9757% of the company's total share capital [1] - The highest price for the repurchased shares was 34.69 CNY per share, while the lowest price was 29.86 CNY per share, with an average repurchase price of 32.39 CNY per share [1] - The total amount spent on the share buyback reached 100.0042 million CNY (excluding transaction fees), achieving the lower limit of the total funds allocated for the buyback plan without exceeding the upper limit [1]

Group 1 - The core point of the article is that Haier Biomedical (688139.SH) has completed its share repurchase program, acquiring a total of 3,087,899 shares, which represents 0.9757% of the company's total share capital [1] - The highest repurchase price was 34.69 CNY per share, while the lowest was 29.86 CNY per share, with an average repurchase price of 32.39 CNY per share [1] - The total amount spent on the repurchase reached 100.0042 million CNY (excluding transaction fees), which is within the limits set by the company's repurchase plan [1]

Core Viewpoint - Haier Bio announced a share repurchase plan, with a total expected repurchase amount of 100 to 200 million yuan, aimed at enhancing shareholder value and supporting employee stock ownership plans [1] Group 1: Share Repurchase Details - The repurchase plan was approved on January 13, 2025, with a repurchase period from January 14, 2025, to January 13, 2026 [1] - As of January 13, 2026, the company completed the repurchase of 3.0879 million shares, accounting for 0.9757% of the total share capital, with a total transaction amount of 100 million 42 thousand yuan [1] - The repurchase price ranged from 29.86 to 34.69 yuan per share [1] Group 2: Shareholder Actions - From January 14 to April 10, 2025, the company's actual controller and concerted party, Haichuangzhi, increased its holdings by 3.8535 million shares, bringing the cumulative shareholding ratio to 2.74% [1]

Group 1 - The core viewpoint of the news is that Haier Biomedical has shown a positive stock performance with a 5.48% increase year-to-date and a market capitalization of 10.609 billion yuan as of January 12 [1] - As of December 31, the number of shareholders for Haier Biomedical is 13,100, a slight decrease of 0.10% from the previous period, while the average circulating shares per person increased by 0.10% to 24,261 shares [2] - The company reported a revenue of 1.761 billion yuan for the period from January to September 2025, reflecting a year-on-year decrease of 1.17%, and a net profit attributable to shareholders of 198 million yuan, down 35.83% year-on-year [2] Group 2 - Haier Biomedical has distributed a total of 788 million yuan in dividends since its A-share listing, with 452 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 6.7302 million shares, an increase of 928,500 shares compared to the previous period, while Huabao Zhongzheng Medical ETF holds 5.4557 million shares, a decrease of 776,900 shares [3]

Core Viewpoint - The company has approved a change in the purpose of repurchased shares, shifting from employee stock ownership plans to cancellation and reduction of registered capital [1]. Group 1: Share Repurchase and Capital Reduction - The company’s board and shareholders have agreed to adjust the use of 1,459,586 repurchased shares from "for employee stock ownership plans or equity incentives" to "for cancellation and corresponding reduction of registered capital" [1]. - The company has completed the necessary registration changes and obtained a new business license reflecting the updated registered capital of 316,492,922 yuan [1]. Group 2: Company Information - The company is named Qingdao Haier Biomedical Co., Ltd., with a unified social credit code of 91370211780374731M, established on October 28, 2005 [1]. - The company operates in various sectors including medical device technology research and development, production, sales, and after-sales services, as well as other related fields [1].

证券代码：688139 证券简称：海尔生物 公告编号：2026-003 青岛海尔生物医疗股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 青岛海尔生物医疗股份有限公司（以下简称"公司"）于2025年10月30日、2025年11月17日分别召开了第 三届董事会第八次会议和2025年第一次临时股东大会，分别审议通过了《关于变更部分回购股份用途并 注销暨减少注册资本的议案》，同意公司将存放于回购专用账户中的1,459,586股已回购股份的用途进行 调整，由"用于员工持股计划或股权激励"调整为"用于注销并相应减少注册资本"，同时按照相关规定办 理注销手续，具体内容详见公司分别于2025年10月31日和2025年11月18日在上海证券交易所网站 （www.sse.com.cn）披露的《青岛海尔生物医疗股份有限公司关于变更部分回购股份用途并注销暨减少 注册资本的公告》（公告编号：2025-049）和《青岛海尔生物医疗股份有限公司2025年第一次临时股东 大会决议公告》（公告编号：2 ...